Eurus Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $5.6M

  • Investors
  • 9

Eurus Therapeutics General Information

Description

Developer of a novel genome editing technology designed to offer advancements in the medical industry. The company develops a new gene therapy with therapeutic strategies that can induce simple and precise genome editing without the use of exogenous proteins such as Cas, enabling the healthcare sector to solve the problems faced by the CRISPR/Cas system.

Contact Information

Website
eurus-tx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2-26-1 Muraokahigashi
  • Fujisawa, Kanagawa
  • Japan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2-26-1 Muraokahigashi
  • Fujisawa, Kanagawa
  • Japan

Eurus Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eurus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 27-Jun-2025 $5.6M Completed Startup
1. Seed Round 29-Sep-2023 Completed Startup
To view Eurus Therapeutics’s complete valuation and funding history, request access »

Eurus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class A-2 Preferred Shares
A Preferred
To view Eurus Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Eurus Therapeutics Patents

Eurus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026094932-A1 Double-stranded nucleotide complex for modification of target nucleotide sequence Pending 29-Oct-2024
JP-2026078993-A Double-stranded nucleotide complexes for alteration of target nucleotide sequences Pending 29-Oct-2024
AU-2024260090-A1 Non-natural polynucleotides for modification of target nucleotide sequence Pending 26-Apr-2023
EP-4703472-A1 Non-natural polynucleotides for modification of target nucleotide sequence Pending 26-Apr-2023
JP-2025092562-A Non-natural polynucleotides for modification of target nucleotide sequence Pending 26-Apr-2023 C12N15/102
To view Eurus Therapeutics’s complete patent history, request access »

Eurus Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eurus Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Kyoto Capital Partners (Japan) Venture Capital Minority
RDiscovery Corporation Corporation Minority
Remiges Ventures Venture Capital Minority
SMBC Venture Capital Corporate Venture Capital Minority
Summit Pharmaceuticals International Corporation Minority
You’re viewing 5 of 9 investors. Get the full list »

Eurus Therapeutics FAQs

  • When was Eurus Therapeutics founded?

    Eurus Therapeutics was founded in 2021.

  • Where is Eurus Therapeutics headquartered?

    Eurus Therapeutics is headquartered in Fujisawa, Japan.

  • What is the size of Eurus Therapeutics?

    Eurus Therapeutics has 10 total employees.

  • What industry is Eurus Therapeutics in?

    Eurus Therapeutics’s primary industry is Drug Discovery.

  • Is Eurus Therapeutics a private or public company?

    Eurus Therapeutics is a Private company.

  • What is the current valuation of Eurus Therapeutics?

    The current valuation of Eurus Therapeutics is .

  • What is Eurus Therapeutics’s current revenue?

    The current revenue for Eurus Therapeutics is .

  • How much funding has Eurus Therapeutics raised over time?

    Eurus Therapeutics has raised $7.23M.

  • Who are Eurus Therapeutics’s investors?

    Kyoto Capital Partners (Japan), RDiscovery Corporation, Remiges Ventures, SMBC Venture Capital, and Summit Pharmaceuticals International are 5 of 9 investors who have invested in Eurus Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process